Jeff Krasnoff | $100M+
THIS PROFILE WAS ADDED THROUGH THE AFFILIATE PROGRAM
Get in touch with Jeff Krasnoff | Jeff Krasnoff, founder and CEO of Rialto Capital Management, built a major real estate investment and asset management platform focused on distressed debt, commercial mortgages, and opportunistic property strategies. After launching Rialto in the aftermath of the financial crisis, Krasnoff helped grow the firm into a leading investor in complex real estate credit and special situations, working with institutional partners across the United States. Known for disciplined underwriting and large-scale capital deployment in dislocated markets, he has positioned Rialto as a significant player in commercial real estate finance.
Disclaimer: This profile is based on publicly available information. No endorsement or affiliation is implied.
Join UHNWI direct Affiliate Program
Earn Passive Income by Sharing Verified Contact Information of Billionaires, Centi-Millionaires, and Multi-Millionaires on the UHNWI Direct Platform
Maximize your earnings potential by sharing direct and validated contact information of the ultra-wealthy, including billionaires, centi-millionaires, and multi-millionaires. Join the UHNWI Direct platform and tap into a lucrative passive income stream by providing valuable data to those seeking high-net-worth connections. Start earning today with UHNWI Direct.
You may also be interested in reviewing other UHNWIs profiles.
To find the person you want to contact, start typing their name or other relevant tags in the search bar.
Please note: Our database contains over 10,000 direct contacts of UHNWIs, and it is highly likely that the individual you are seeking is already included. However, creating individual profiles for each contact is a meticulous and time-intensive process, So, if you are unable to find the profile of the individual you are looking for, please click here.
Filter by Net Worth: All | Billionaires | Centi-Millionaires | Multi-Millionaires
Filter by Location: All | USA | Canada | Europe | UK | Russia & CIS | Asia | MEIA | Australia | Latin America
Filter by Age: 1920-1930 | 1930-1940 | 1940-1950 | 1950-1960 | 1960-1970 | 1970-1980 | 1980-1990 | 1990-2000
Related People
Jeff Krasnoff, cofounder and managing principal of Rialto Capital Management, built a major real estate investment and asset management platform focused on distressed debt, commercial mortgages, and opportunistic property strategies. After launching Rialto in the aftermath of the financial crisis, Krasnoff helped grow the firm into a leading investor in complex real estate credit and special situations, working with institutional partners across the United States. Known for disciplined underwriting and large-scale capital deployment in dislocated markets, he has positioned Rialto as a significant player in commercial real estate finance.
Wayne Hughes Jr., chairman of Public Storage, oversees one of the largest self-storage empires in the world, continuing the legacy built by his father, company founder Wayne Hughes. After years in private investing and philanthropy, he assumed a leading role in the publicly traded REIT, guiding strategy across a vast portfolio of storage properties throughout the United States and Europe. Known for low-profile leadership and long-term ownership discipline, Hughes represents a new generation of stewardship within one of the most profitable real estate business models in modern property investing.
Alan Smolinisky is a billionaire entrepreneur, principal at Conquest Housing, and co-owner of the Los Angeles Dodgers. He first built his fortune with Conquest Student Housing, which became the largest provider at USC before selling for $205 million in 2008. In 2026, he serves as a director at Jack in the Box, chairing its Capital Allocation Committee following a late 2025 appointment. A dedicated value investor and philanthropist, he has committed 90% of his estate to charity and is a vocal advocate for immigration reform, famously hosting mass naturalization ceremonies at Dodger Stadium. He remains a key figure in sports business, previously partnering with Phil Knight on a $2 billion bid for the Portland Trail Blazers.
Thomas Barrack Jr. is the U.S. Ambassador to Türkiye and the Special Envoy for Syria in the second Trump administration, where he serves as a pivotal figure in Middle Eastern diplomacy. A veteran private equity investor and the founder of Colony Capital (now DigitalBridge), Barrack has leveraged his decades of experience in the region to broker historic regional agreements. In early 2026, he played a lead role in integrating the Syrian government into the Global Coalition to Defeat ISIS and oversaw major infrastructure MoUs, including a milestone gas exploration agreement between Syria and Chevron. His current diplomatic portfolio emphasizes regional security through "shared responsibility," successfully managing the complex transition of territory between the Syrian Democratic Forces and the central government in Damascus.
Stewart Rahr is the billionaire founder of Kinray, which he grew into the largest privately held pharmaceutical distributor in the world before its $1.3 billion sale to Cardinal Health in 2010. Known as the self-styled "Number One King of All Fun," Rahr is a permanent fixture in New York’s high-society and philanthropic circles. His Stewart J. Rahr Foundation has donated over $25 million to the Make-A-Wish Foundation alone, alongside significant contributions to cancer and medical research. A flamboyant figure with a reputation for grand charity galas and celebrity connections, he remains a central force in American philanthropy and land stewardship in the Hamptons.
Steven Klinsky is the founder and CEO of New Mountain Capital, a private equity firm that manages over $50 billion in assets and focuses on high-growth, non-cyclical businesses. Before founding his firm in 1999, he was a pioneer in the industry at Goldman Sachs and a general partner at Forstmann Little, where he helped develop the strategy of business-building over financial engineering. Klinsky is also a major figure in education reform, having established the Modern States Education Alliance, which provides free college-level courses and credit to hundreds of thousands of students globally.
Stephane Bancel is the CEO of Moderna, the biotechnology firm that gained global prominence for its pioneering use of messenger RNA (mRNA) technology. Since taking the helm in 2011, Bancel transitioned the company from a pre-clinical startup into a commercial powerhouse, most notably leading the rapid development and global distribution of one of the first COVID-19 vaccines. His leadership is characterized by an aggressive "platform" approach to drug development, aiming to treat everything from rare genetic diseases to cancer and respiratory viruses by turning human cells into drug factories. Under his tenure, Moderna has become a symbol of the genomic revolution, reshaping the pharmaceutical industry’s traditional R&D timelines.
Robert Duggan, biotech entrepreneur and investor, built his fortune by identifying overlooked medical assets and scaling them into blockbuster businesses. He is best known for leading Pharmacyclics as CEO and majority owner, turning the company into a major oncology success through the development of Imbruvica, before selling it to AbbVie in a multibillion-dollar deal. Known for bold conviction, aggressive capital deployment, and a willingness to bet heavily on scientific outcomes, Duggan has become one of the most successful dealmakers in modern biotechnology.
Richard Peery, founder of the Peery family real estate enterprise, built one of Silicon Valley’s most influential commercial property portfolios by specializing in high-quality office and industrial developments in Northern California. Known for acquiring and developing strategic assets near the world’s leading technology corridors, Peery helped shape the physical infrastructure that supported the region’s growth for decades. Operating with a low public profile, he expanded through long-term ownership, disciplined management, and a deep understanding of location-driven value. Peery is also recognized for philanthropy supporting education, community development, and civic initiatives.
Richard LeFrak, chairman and CEO of LeFrak Organization, leads one of America’s most enduring real estate dynasties, overseeing a vast portfolio of residential, commercial, and mixed-use assets. Building on the legacy of his father Samuel LeFrak, he expanded the family’s holdings across New York, New Jersey, and Florida, including landmark developments such as Newport in Jersey City. Known for long-term ownership, disciplined capital deployment, and large-scale urban development, LeFrak has shaped major waterfront and city-center projects while maintaining the firm as a privately held powerhouse.
Richard Kurtz, founder and chairman of Kamson Corporation, built a major privately held real estate company specializing in multifamily and mixed-use properties across the Northeastern United States. Starting with a focus on apartment ownership and management, Kurtz grew Kamson through disciplined acquisitions, property repositioning, and long-term operational control, creating a large portfolio spanning residential communities and commercial assets. Known for quiet execution and a patient, cash-flow-driven strategy, he has maintained Kamson as a durable family-led platform through multiple real estate cycles.
Raymond J. Harbert, founder and CEO of Harbert Management Corporation, built a major alternative investment platform spanning private equity, real estate, infrastructure, and credit. After starting his career in banking and leveraged finance, Harbert founded his firm in 1993 and grew it into a global manager serving institutions and high-net-worth investors with long-term, diversified strategies. Known for disciplined capital allocation and a conservative, steady approach across market cycles, Harbert has also become a prominent philanthropist supporting education, medical research, and civic initiatives, particularly in the American South.
Randal J. Kirk, biotech entrepreneur and investor, built his fortune by creating and scaling life-sciences companies focused on drug development, specialty pharmaceuticals, and healthcare innovation. Best known as the founder of Intrexon and as the driving force behind multiple public biotech ventures, Kirk has pursued an aggressive strategy of acquiring scientific platforms, recruiting top research talent, and commercializing high-value therapies. His long-term influence spans pharmaceuticals, genetics, and medical technology, reflecting a rare ability to combine capital markets skill with scientific ambition.
Purnendu Chatterjee, founder and chairman of The Chatterjee Group, built a diversified global investment firm by taking concentrated, long-term positions in industrial, chemical, consumer, and infrastructure businesses. A former partner at Soros Fund Management, Chatterjee applies activist discipline and operational focus to complex situations, often partnering closely with management to drive strategic change. His portfolio has included significant stakes across the U.S., Europe, and Asia, reflecting a patient, hands-on approach to value creation.
Phillip Frost, physician and entrepreneur, built a biotechnology empire by identifying undervalued medical assets and scaling them through disciplined science-driven investing. As founder and chairman of OPKO Health, Frost assembled a diversified healthcare platform spanning diagnostics, pharmaceuticals, and medical technologies, often through strategic acquisitions and partnerships. Earlier in his career, he sold IVAX Corporation to Teva in a multibillion-dollar transaction, cementing his reputation as a leading dealmaker in life sciences. Known for a long-term approach to innovation and capital allocation, Frost remains a central figure in global healthcare entrepreneurship.
Philip Milstein, founder and CEO of Ogden CAP Properties, built a major New York–based real estate investment platform focused on value-oriented acquisitions across office, residential, and mixed-use properties. After early experience in property development and asset management, Milstein expanded Ogden CAP by targeting complex, underperforming assets and repositioning them through active management and long-term capital discipline. Known for a hands-on approach and deep market knowledge, he has assembled a sizable portfolio while maintaining a low public profile. Milstein’s career reflects patient investing and contrarian thinking within urban real estate markets.
Peter Thiel, cofounder of PayPal and Palantir Technologies, is one of Silicon Valley’s most influential and contrarian thinkers, known for backing companies that challenge consensus and reshape entire industries. As an early investor in Facebook and the first outside investor in several category-defining startups, Thiel helped popularize a philosophy centered on building monopolies through deep technology rather than incremental competition. Through Founders Fund, he has backed transformative ventures across software, defense, biotech, and space. Thiel’s impact extends beyond investing into ideas, shaping debates around technology, globalization, and the future of innovation.
Peter Gassner, cofounder and CEO of Veeva Systems, built one of the most successful vertical software companies by focusing exclusively on cloud solutions for the life sciences industry. After an early career at Salesforce, where he helped scale enterprise cloud adoption, Gassner launched Veeva in 2007 to serve pharmaceutical and biotech companies with regulated, mission-critical applications. Under his leadership, Veeva became a publicly traded, highly profitable software company known for deep industry specialization, long-term customer relationships, and disciplined execution. Gassner’s approach exemplifies the power of focus and vertical expertise in enterprise software.
Patrick Soon-Shiong, physician, biotech entrepreneur, and investor, built one of the most consequential careers at the intersection of medicine, science, and capital. After developing the cancer drug Abraxane, which he sold to Celgene in a multibillion-dollar deal, Soon-Shiong went on to found and back numerous life-sciences companies focused on immunotherapy, data-driven medicine, and personalized healthcare. Beyond biotech, he is the owner of the Los Angeles Times and has invested heavily in medical research, AI-enabled health systems, and pandemic preparedness. His work reflects a long-term ambition to reengineer healthcare around biology, data, and scalable innovation.
Pablo Legorreta, founder and CEO of Royalty Pharma, built a category-defining firm by pioneering royalty-based investing in biopharmaceutical innovation. After founding the company in 1996, Legorreta created a model that provides non-dilutive capital to drug developers in exchange for royalty streams on approved medicines, helping finance breakthroughs while managing risk through diversified cash flows. Under his leadership, Royalty Pharma scaled into a multibillion-dollar, publicly traded platform that partners with leading biotech companies and academic institutions worldwide, reshaping how life-science innovation is funded.
Osman Kibar, founder and CEO of Samara, is a biotech entrepreneur focused on regenerative medicine, aiming to restore organ function rather than manage disease. Trained as a materials scientist, Kibar launched Samara to develop therapies that activate the body’s innate repair mechanisms, starting with severe osteoarthritis. By combining developmental biology with advanced drug discovery, he has positioned the company at the frontier of tissue regeneration. Kibar’s work reflects a long-horizon approach to biotech innovation centered on curative science.
Nicolas Berggruen, investor and philanthropist, built a global reputation as a contrarian thinker blending capital, policy, and long-term societal vision. Founder of Berggruen Holdings and the Berggruen Institute, he has invested across real estate, finance, and special situations while championing ideas around governance reform, technology, and globalization. Known for his unconventional lifestyle and intellectual focus, Berggruen has positioned himself less as a traditional financier and more as a patron of cross-disciplinary thought, convening global leaders to address structural challenges facing modern societies.
Mortimer Zuckerman, real estate magnate, media executive, and investor, built a multifaceted career spanning property development, publishing, and public policy influence. As longtime chairman and CEO of Boston Properties, he helped create one of the largest publicly traded office real estate investment trusts in the United States, shaping skylines in New York, Boston, and Washington, D.C. In parallel, Zuckerman became a prominent media figure as owner and editor-in-chief of U.S. News & World Report and publisher of the New York Daily News, using his platforms to weigh in on economics, foreign policy, and urban affairs. His career reflects a rare blend of large-scale real estate execution and national media influence.
Lowell Milken, cofounder of Knowledge Universe and a longtime leader in education reform and philanthropy, has built a wide-ranging career focused on improving teaching quality and expanding access to effective learning models. After an early career in law and finance, he helped develop Knowledge Universe into one of the world’s largest private education companies, spanning early childhood learning, professional development, and technology-enabled instruction. As chairman of the Milken Family Foundation, he has created nationally recognized programs such as the Milken Educator Awards and TAP: The System for Teacher and Student Advancement. Known for his strategic vision and commitment to education innovation, Milken is a defining figure in modern philanthropic efforts to strengthen America’s schools.
Leonard Schleifer, cofounder and CEO of Regeneron Pharmaceuticals, built one of the most successful biotech companies in the world by combining scientific rigor with long-term investment in research. A trained neurologist turned entrepreneur, he launched Regeneron in 1988 and steered it through decades of discovery to blockbuster drugs such as Eylea, Dupixent, and leading monoclonal antibody therapies. Under his leadership, Regeneron became known for its genetics platform, deep scientific culture, and partnerships that accelerated medical breakthroughs. Schleifer’s blend of clinical expertise, business discipline, and research focus has made him a defining figure in the modern biotechnology landscape.
Leo KoGuan, billionaire entrepreneur and founder of SHI International, built one of America’s largest privately held IT services companies, supplying software, cloud infrastructure, and enterprise solutions to Fortune 500 clients. A bold technology investor, he is also known as one of the biggest individual shareholders of Tesla, publicly advocating for the company’s mission and long-term strategy. Born in Indonesia and educated in the United States, KoGuan combines global business reach with significant philanthropy, supporting universities, research, and cultural institutions across Asia and the U.S. His career reflects scale, conviction, and a relentless focus on technological progress.
Christian Dumolin, chairman and co-ceo of Koramic Investment Group, is one of Belgium’s most respected industrial and investment leaders, known for transforming a traditional brick-manufacturing company into a diversified European holding with interests spanning real estate, manufacturing, financial services, and private equity. After joining the family business in the 1970s, he led its international expansion, later steering Koramic into a broad investment platform focused on long-term value creation and operational excellence. Dumolin has served on numerous corporate boards, becoming a key figure in Belgium’s entrepreneurial landscape, while his philanthropic work in culture, education, and regional development underscores his influence beyond business.
Marc Coucke, Belgian entrepreneur and investor, built his fortune as the cofounder of Omega Pharma, transforming a small over-the-counter medicine distributor into one of Europe’s largest consumer healthcare companies before selling it to Perrigo for billions. After the sale, Coucke diversified through his investment company Alychlo, acquiring and backing businesses across pharmaceuticals, hospitality, sports, real estate, and leisure—including theme parks, luxury resorts, and the Belgian football club R.S.C. Anderlecht. Known for his charismatic style, bold dealmaking, and expansive portfolio, Coucke has become one of Belgium’s most influential business figures, blending entrepreneurial drive with high-profile investments across Europe.
Joseph Chetrit, founder of the Chetrit Group, is one of New York’s most enigmatic and influential real estate investors, known for executing some of the city’s largest and most complex property deals with minimal public profile. After building an early fortune in textiles, Chetrit shifted into real estate in the 1990s, assembling a multibillion-dollar portfolio that includes office towers, residential conversions, hotels, and landmark properties across Manhattan, Miami, Los Angeles, and beyond. His firm has been involved in major transactions such as the Sears Tower sale, the Chelsea Hotel redevelopment, and large-scale waterfront projects. Chetrit’s combination of discretion, scale, and contrarian timing has made him a defining—if quietly spoken—force in American real estate.
Jonathan Gray, president and chief operating officer of Blackstone, is one of the most influential investors in modern finance, credited with building the firm’s real estate arm into the world’s largest private property platform. Joining Blackstone in 1992, he pioneered the company’s massive expansion into opportunistic real estate, logistics, hospitality, and large-scale global acquisitions, including the Hilton Hotels deal—one of the most profitable private equity investments in history. As COO, Gray now helps steer Blackstone’s multi-trillion-dollar asset management strategy across private equity, credit, infrastructure, and insurance. Known for his analytical discipline, bold dealmaking, and philanthropic leadership in cancer research, Gray is a central architect of the firm’s rise to global dominance.
